| Methods of treatment for cystic fibrosis |
2023-7-31 |
2023-8-17 |
|
| Modulator of cystic fibrosis transmembrane conductance regulator, … |
2023-6-22 |
2023-7-13 |
|
| Pteridinone compounds and uses thereof |
2023-6-15 |
2023-8-22 |
|
| MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF THE … |
2023-5-17 |
2023-8-15 |
|
| Devices and methods for delivering therapeutic agents |
2023-5-08 |
2023-7-19 |
|
| Cystic fibrosis transmembrane conductance regulator modulators |
2023-5-05 |
2023-7-21 |
|
| Re-aggregation of stem cell-derived pancreatic beta cells |
2023-3-28 |
2023-6-16 |
|
| apol1 inhibitors and methods of using the same |
2023-3-13 |
2023-3-17 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2023-3-07 |
2023-4-06 |
|
| Substituted quinoxaline dna-pk inhibitors |
2023-2-27 |
2023-9-07 |
|
| Cystic fibrosis transmembrane conductance regulator modulators |
2023-2-24 |
2023-5-19 |
|
| Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates … |
2023-2-22 |
2023-6-15 |
|
| GCN2 inhibitors and uses thereof |
2023-2-14 |
2023-4-20 |
|
| Modified urokinase-type plasminogen activator polypeptides and methods of use |
2023-2-10 |
2023-8-03 |
|
| Modulators of alpha-1 antitrypsin |
2023-2-09 |
2023-8-24 |
|
| 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as … |
2023-2-08 |
2023-8-17 |
|
| Inhibitors of apol1 and methods of using same |
2023-2-07 |
2023-8-31 |
|
| Methods of treatment for cystic fibrosis |
2023-2-02 |
2023-8-10 |
|
| Cell therapy for diabetes |
2023-1-31 |
2023-8-10 |
|
| Materials and methods for treating duchenne muscular dystrophy |
2022-12-14 |
2023-3-15 |
|
| Carboxamides as modulators of sodium channels |
2022-12-13 |
2023-9-14 |
|
| Differentiation of pancreatic endocrine cells |
2022-11-16 |
2023-3-23 |
|
| Stem cell derived islet differentiation |
2022-11-14 |
2023-3-09 |
|
| Methods of enhancing stem cell differentiation into beta cells |
2022-11-11 |
2023-5-04 |
|
| Substituted tetrahydrofurans as modulators of sodium channels |
2022-11-08 |
2023-9-14 |
|
| Stem cell differentiation and chemical compounds |
2022-11-07 |
2023-5-11 |
|
| Method for treating cancer using a combination of DNA damaging agents and ATR … |
2022-10-20 |
2022-11-24 |
|
| Materials and methods for treatment of pain related disorders |
2022-10-19 |
2022-12-22 |
|
| Materials and methods for treatment of pain related disorders |
2022-10-03 |
2023-9-07 |
|
| Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- … |
2022-9-27 |
2023-8-24 |
|
| Macrocycles as modulators of cystic fibrosis transmembrane conductance … |
2022-9-15 |
2022-10-06 |
|
| CRYSTALLINE FORMS OF C21H22Cl2N4O2 |
2022-9-05 |
2022-9-29 |
|
| Method for treating cancer using combination of dna-damaging agents and dna-pk … |
2022-7-25 |
2022-9-15 |
|
| Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other … |
2022-6-28 |
2023-7-20 |
|
| Compounds useful as inhibitors of atr kinase |
2022-6-23 |
2023-8-31 |
|
| Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium … |
2022-6-03 |
2022-12-08 |
|
| N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of … |
2022-6-03 |
2023-1-12 |
|
| Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
2022-6-03 |
2022-12-08 |
|
| N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators … |
2022-6-03 |
2022-12-08 |
|
| Administration of deuterated cftr potentiators |
2022-3-20 |
2022-5-01 |
|
| Modulators of atp-binding cassette transporters |
2022-3-11 |
2023-4-27 |
|
| Stem cell differentiation and polymers |
2022-3-08 |
2022-9-15 |
|
| Crystal forms of cftr modulators |
2022-3-04 |
2022-6-21 |
|
| Manufacturing process of cftr modulators |
2022-3-04 |
2022-6-21 |
|
| Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of … |
2022-3-02 |
2022-3-24 |
|
| Compositions and methods for treatment of myotonic dystrophy type 1 with crispr … |
2022-2-25 |
2022-9-01 |
|
| Compositions and Methods for Treatment of Disorders Associated with Repetitive … |
2022-2-25 |
2022-6-16 |
|
| Materials and methods for treatment of hemoglobinopathies |
2022-2-02 |
2022-7-07 |
|
| TABLET FOR THE TREATMENT OF DISEASES MEDIATED BY CFTR |
2022-2-01 |
2023-5-03 |
|
| Materials and methods for treatment of hemoglobinopathies |
2022-1-26 |
2022-8-18 |
|
| Enhanced differentiation of beta cells |
2021-12-28 |
2023-7-06 |
|
| Pharmaceutical compositions for treating cftr-mediated diseases |
2021-12-28 |
2022-3-02 |
|
| Enhanced differentiation of beta cells |
2021-12-23 |
2022-7-28 |
|
| Compositions comprising an rna guide targeting dmd and uses thereof |
2021-12-21 |
2022-6-30 |
|
| Methods of treating cystic fibrosis |
2021-12-09 |
2023-9-29 |
|
| Condensed tricyclic pyrroles as modulators of alpha-1 antitrypsin |
2021-12-07 |
2022-4-29 |
|
| Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3- … |
2021-11-25 |
2022-1-01 |
|
| Compositions and methods for treatment of dm1 with slucas9 and sacas9 |
2021-11-05 |
2022-5-12 |
|
| Cystic fibrosis transmembrane conductance regulator modulating agents |
2021-10-25 |
2021-10-29 |
|
| Modulator of cystic fibrosis transmembrane conductance regulator, … |
2021-10-20 |
2022-9-29 |
|
| MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS |
2021-10-07 |
2023-1-04 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2021-10-07 |
2022-8-01 |
|
| MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR |
2021-10-07 |
2022-5-31 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2021-10-06 |
2023-8-29 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2021-10-06 |
2022-4-14 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2021-10-06 |
2022-4-14 |
|
| Modulators of cystic fibrosis transmembrane conductance regulator |
2021-10-06 |
2022-4-14 |
|
| Method for treating cancer using a combination of chk1 and atr inhibitors |
2021-9-20 |
2022-8-11 |
|
| Methods, compositions and kits for increasing genome editing efficiency |
2021-9-17 |
2021-10-14 |
|
| Formulations of azaindole compounds |
2021-9-17 |
2021-12-16 |
|
| Pharmaceutical composition and administrations thereof |
2021-9-15 |
2022-8-04 |
|
| Pharmaceutical compositions for treating cystic fibrosis |
2021-9-15 |
2022-8-18 |
|
| Compositions and Methods for Treatment of Duchenne Muscular Dystrophy |
2021-9-08 |
2022-3-31 |
|
| Compositions and methods for treating duchenne muscular dystrophy |
2021-9-08 |
2023-8-01 |
|
| Crystalline Forms of CFTR Modulators |
2021-8-12 |
2023-4-17 |
|
| Compounds useful as inhibitors of atr kinase and combination therapies thereof |
2021-8-03 |
2022-7-28 |
|
| In vitro differentiation of pancreatic endocrine cells |
2021-7-30 |
2022-2-03 |
|
| Process of conducting high throughput testing high performance liquid … |
2021-7-26 |
2021-10-29 |
|
| PROCESSES FOR PREPARING ALPHA-1 ANTITRYPSIN MODULATORS |
2021-7-26 |
2023-4-11 |
|
| Processes and intermediate compounds for producing atr kinase inhibitor … |
2021-7-14 |
2021-8-31 |
|
| Methods of preparing inhibitors of influenza viruses replication |
2021-7-12 |
2021-8-05 |
|
| Methods of preparing pharmaceutical compositions for treatment of cftr mediated … |
2021-7-06 |
2021-10-14 |
|
| Modulators of atp-binding cassette transporters |
2021-6-29 |
2022-5-19 |
|
| Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane … |
2021-6-28 |
2021-9-17 |
|
| COMPLEMENT FACTOR I RELATED COMPOSITIONS AND METHODS |
2021-6-14 |
2023-7-10 |
|
| Inhibitors of APOL1 and use of the same |
2021-6-11 |
2023-1-19 |
|
| Solid forms of apol1 inhibitor and using the same |
2021-6-11 |
2023-1-01 |
|
| Inhibitors of APOL1 and use of the same |
2021-6-11 |
2023-1-19 |
|
| Deuterated derivatives of ivacaftor |
2021-6-08 |
2023-3-16 |
2023-3-16 |
| Treatment methods for cystic fibrosis |
2021-6-08 |
2021-12-10 |
|
| Gene-editing systems for editing a cystic fibrosis transmembrane regulator ( … |
2021-6-04 |
2021-12-30 |
|
| Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) … |
2021-5-28 |
2022-2-03 |
|
| Modulators of alpha-1 antitrypsin |
2021-4-06 |
2022-3-01 |
|
| 1H-pyrazolo [4,3-g ] isoquinoline and 1H-pyrazolo [4,3-g ] quinoline … |
2021-4-02 |
2023-2-24 |
|
| Modulators of alpha-1 antitrypsin |
2021-4-02 |
2022-10-20 |
|
| Pyrrolo[2,3-F]indazole derivatives and 2,4,5,10-tetraazatricyclo[7.3.0.03 as … |
2021-4-02 |
2022-12-09 |
|
| Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating … |
2021-4-02 |
2023-5-25 |
|
| Methods of treating APOL-1 dependent focal segmental glomerulosclerosis |
2021-3-05 |
2023-4-13 |
|
| Dna-pk inhibitors |
2021-3-03 |
2021-4-16 |
|
| Pyridone amides as modulators of sodium channels |
2021-3-01 |
2021-4-16 |
|